Curis Inc. - Rasio total nilai perusahaan marang pendapatan CRIS

Curis, Inc. (CRIS) develops innovative small molecules to combat oncology, creating less toxic therapy methods. The enterprise value-to-revenue ratio helps compare market valuation with business scale, with -315.79 representing the latest metric reading. Management's effective control of R&D costs complements the company's dependence on strict FDA protocols and patient participation in trials.
CRIS (Curis Inc.): rincian analitis lan laporan miturut indikator

While the market has already priced in the development costs of the leukemia inhibitor, the anticipation of Phase 2 data renders revenue a secondary valuation factor for Curis, Inc. (CRIS). This metric compares the enterprise value (EV) to sales, excluding the impact of leverage to determine the actual price of one dollar of revenue. By analyzing the enterprise value-to-revenue trend, an investor can observe the rate of multiple compression relative to the market trend.